The management of EGFR inhibitor adverse events: A case series and treatment paradigm

International Journal of Dermatology

Volumn 51, Issue 2, 2012, Pages 223-232

  Wnorowski, Amelia M ^a   de Souza, Aieska ^a   Chachoua, Abraham ^a   Cohen, David E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETAMETHASONE; CALCIPOTRIOL; CETIRIZINE; CETUXIMAB; CICLOPIROX; CLINDAMYCIN; CLOBETASOL; DOXYCYCLINE; ERLOTINIB; FLUOCINOLONE; METRONIDAZOLE; MINOXIDIL; MOXIFLOXACIN; PIMECROLIMUS; SALICYLIC ACID; TACROLIMUS; UREA;

ADULT; AGED; ALOPECIA; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG WITHDRAWAL; ECZEMA; EXUDATE; FEMALE; GRANULATION TISSUE; HERPES ZOSTER; HUMAN; HYPERKERATOSIS; INOPERABLE CANCER; INTERTRIGO; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; NAIL; PANCREAS CANCER; PARONYCHIA; PODIATRY; PRURITUS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STEROID THERAPY; STEVENS JOHNSON SYNDROME; TOPICAL TREATMENT; XEROSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855919382     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05082.x     Document Type: Article

References (35)

1. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF-receptor. Cell 2002; 110: 669-672.
2. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670.
3. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
4. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
5. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
6. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149-2158.
7. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38-44.
8. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165-174.
9. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
10. Federal Drug Administration: Drugs @ FDA, daily update.
11. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-1176.
12. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
13. Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-621.
14. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 232-257.
15. Baselga J, Rischi D, Ransom M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
16. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008; 58: 545-570.
17. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III Trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
18. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13: 1201-1204.
19. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-326.
20. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009; 15: 4.
21. Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115: 1286-1299.
22. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J Clin Oncol 2002; 20: 2240-2250.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
24. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
25. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64: 9139-9143.
26. Carlson JJ, Garrison LP, Ramsey SD, et al. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2009; 135: 1483-1493.
27. Guillamo JS, de Boüard S, Valable S, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res 2009; 15: 3697-3704.
28. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 9: 145.
29. Tangri N, Al Hammadi A, Gerstein W. Epidermal growth factor receptor inhibitor-related folliculitis. Dermatitis 2007; 18: 178-179.
30. Pérez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
31. Shepherd FA, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
32. Santoro F, Cozzani E, Parodi A. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor. J Dermatolog Treat 2006; 17: 160-161.
33. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor Rash Management Forum. Oncologist 2005; 10: 345-356.
34. National Cancer Institute. Common terminology criteria for adverse events v4.0, 5/2009 update.
35. Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13: 3413-3422.